OncoMatch

OncoMatch/Clinical Trials/NCT06428409

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Is NCT06428409 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for colorectal cancer.

Phase 1/2RecruitingMerck Sharp & Dohme LLCNCT06428409Data as of May 2026

Treatment: Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin · Rescue medication · Supportive care measures · Cisplatin · PembrolizumabResearchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Pancreatic Cancer

Cholangiocarcinoma

Disease stage

Required: Stage IV

Unresectable or metastatic colorectal cancer; Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC); Advanced and/or unresectable biliary tract cancer (BTC)

Prior therapy

Must have received: systemic anticancer therapy

has received prior therapy for the cancer

Cannot have received: systemic anticancer therapy

Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UCLA ( Site 0317) · Los Angeles, California
  • University of Colorado Anschutz Medical Campus ( Site 0299) · Aurora, Colorado
  • University of Colorado Anschutz Medical Campus ( Site 0325) · Aurora, Colorado
  • University of Colorado Anschutz Medical Campus ( Site 0326) · Aurora, Colorado
  • Sibley Memorial Hospital ( Site 0310) · Washington D.C., District of Columbia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify